Trials / Completed
CompletedNCT04230044
A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy
A Post Marketing Observational Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Epilepsy Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 117 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety and efficacy of Fycompa® (perampanel) for the adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in participants with epilepsy aged 12 years and older.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Perampanel | Perampanel tablets. |
Timeline
- Start date
- 2016-04-11
- Primary completion
- 2017-07-03
- Completion
- 2017-07-03
- First posted
- 2020-01-18
- Last updated
- 2020-01-18
Source: ClinicalTrials.gov record NCT04230044. Inclusion in this directory is not an endorsement.